Masthead (4k)

[News Index (0.5k)]
[Current News and Info (0.5k)]
[2007 (0.5k)]
[2006 (0.5k)]
[2005 (0.5k)]
[2004 (0.5k)]
[2003 (0.5k)]
[2002 (0.5k)]
[2001 (0.5k)]
[2000 (0.5k)]
[1999 (0.5k)]
[1998 (0.5k)]
[1997 (0.5k)]
[1996 (0.5k)]
[1995 (0.5k)]
[Really Old News (0.5k)]

Contents: News Stories, 2001


October 9, 2001

Nanoprobes Receives Phase 1 SBIR Grant on Enzyme Metallography for Biological Detection from NIGMS

The National Institute of General Medical Sciences (National Institutes of Health) has recently awarded a Phase I SBIR grant to Nanoprobes, Incorporated (Yaphank, NY) of $ 106,000 for six months, effective September 24, 2001, to research and develop a novel enzymatically mediated metal deposition reaction for biological detection and staining.

The new detection system utilizes the selective deposition of metal from solution onto specific sites within cells and tissues labeled with an enzyme-linked antibody or other biomolecule conjugate targeted to the sites of interest. In preliminary blotting and staining experiments, it has been found to give high sensitivity combined with high spatial and detail resolution within samples, making it useful both for the identification and quantitation of cellular features for disease identification, and for microscopic and ultrastructural investigation. This technology will be developed for use as a general staining and detection method for the immunohistochemical staining of proteins, and also in situ hybridization detection of genetic changes in cells and tissue sections. The method is straightforward, and compared with current methods, has the potential advantages of greater speed and simplicity as well as improved sensitivity and resolution.

The chemistry of the new detection system will be developed and optimized at Nanoprobes, Incorporated by Dr. Richard D. Powell, Dr. James F. Hainfeld, Dr. Wenqiu Liu and Dr. Vishwas Joshi. Further optimization and testing in immunohistochemical staining and in situ hybridization experiments will be conducted by Dr. Raymond R. Tubbs, Dr. Linda Vargo, and James D. Pettay at the Cleveland Clinic Foundation (Cleveland, OH).

Nanoprobes, Inc., founded in November 1990, researches and develops the biomedical and high-technology applications of metal nanoparticles and autometallography. The company is a leader in immunogold technology, with products which include the 1.4 nm Nanogold® cluster immunoprobes and labeling reagents, the combined fluorescent and gold immunoprobe FluoroNanogold which is used for correlative fluorescence and electron microscopy, and sensitive DNA detection reagents.

For more information, contact:

Richard D. Powell, Ph. D.
Research Director
Nanoprobes, Incorporated
95 Horse Block Road
Yaphank, NY 11980-2301

Telephone: (919) 845-6324
Fax: (631) 980-3608
E-mail rpowell@nanoprobes.com.
WWW: www.nanoprobes.com

contents


October 9, 2001

Nanoprobes Reagents Now Available from Molecular Probes

Nanogold® reagents and select conjugates are now available from Molecular Probes, Incorporated under a supply and distribution agreement. Products included in this agreement include our unique 1.4 nm Nanogold® site-specific gold labeling reagents, Fab secondary antibody and streptavidin conjugates, and silver enhancement reagents. By including these products in the widely distributed Molecular Probes Handbook of Fluorescent Probes, the companies anticipate that these probes will be introduced to more customers, and will enable microscopists who routinely use products from Molecular Probes wide range of fluorescent labeling reagents to conveniently order high-quality electron microscopy labeling reagents from the same source to extend their studies to the electron microscope.

Nanoprobes, Incorporated and Molecular Probes plan to offer additional products and new reagents under this agreement in the future, including our line of FluoroNanogold combined fluorescent and gold probes. New products currently pending commercial release include combined fluorescent and gold probes labeled with Molecular Probes ALEXA fluorescent dyes. These are expected to offer improved performance over the fluorescein and Nanogold conjugates, and will enable correlative fluorescent and electron microscopy labeling at different wavelengths.

Nanoprobes, Inc., founded in November 1990, researches and develops the biomedical and high-technology applications of metal nanoparticles and autometallography. The company is a leader in immunogold technology, with products which include the 1.4 nm Nanogold® cluster immunoprobes and labeling reagents, the combined fluorescent and gold immunoprobe FluoroNanogold which is used for correlative fluorescence and electron microscopy, and sensitive DNA detection reagents.

For more information, contact:

James F. Hainfeld, Ph. D.
President
Nanoprobes, Incorporated
95 Horse Block Road
Yaphank, NY 11980-2301

Telephone: (631) 205-9490
Fax: (631) 205-9493
E-mail nano@nanoprobes.com.
WWW: www.nanoprobes.com

contents


 

View Cart     Nanoprobes.com
© 1990-2017 Nanoprobes, Inc. All rights reserved. Sitemap